{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:21:38Z","timestamp":1791976898278,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006736","name":"Universitetssjukhuset \u00d6rebro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014195","name":"Region V\u00e4rmland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014195","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Epidemiol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Backgound and Aims<\/jats:title>\n                <jats:p>Previous research on the potential chemoprotective effect of aspirin for colorectal cancer (CRC) shows conflicting results. We aimed to emulate a trial of aspirin intiation in individuals with incident polyps.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We identified individuals registered with their first colorectal polyp in the nationwide gastrointestinal ESPRESSO histopathology cohort in Sweden. Individuals aged 45\u201379\u00a0years diagnosed with colorectal polyps 2006\u20132016 in Sweden without CRC or contraindications for preventive aspirin (cerebrovascular disease, heart failure, aortic aneurysms, pulmonary emboli, myocardial infarction, gastric ulcer, dementia, liver cirrhosis, or any other metastatic cancer) registered until the month of first polyp detection were eligible. Using duplication and inverse probability weighting, we emulated a target trial of aspirin initiation within 2\u00a0years of initial polyp detection. The main outcome measures were incident CRC, CRC mortality and all-cause mortality registered until 2019.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 31,633 individuals meeting our inclusion criteria, 1716 (5%) initiated aspirin within 2\u00a0years of colon polyp diagnosis. Median follow-up was 8.07\u00a0years. The 10-year cumulative incidence in initiators versus non-initiators was 6% versus 8% for CRC incidence, 1% versus 1% for CRC mortality and 21% versus 18% for all-cause mortality. The corresponding hazard ratios were 0.88 (95% confidence interval, 95%CI\u2009=\u20090.86\u20130.90), 0.90 (95%CI\u2009=\u20090.75\u20131.06) and 1.18 (95%CI\u2009=\u20091.12\u20131.24).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Aspirin initiation in individuals with polyp removal was linked to 2% lower cumulative incidence of CRC after 10\u00a0years but did not alter CRC mortality. We also observed a 4% increased risk difference of all-cause mortality at 10\u00a0years after the initiation of aspirin.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10654-023-01024-1","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T16:02:17Z","timestamp":1686844937000},"page":"1105-1114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Target trial emulation of aspirin after diagnosis of colorectal polyps"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9137-2800","authenticated-orcid":false,"given":"Louise","family":"Emilsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas F.","family":"Ludvigsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"6","key":"1024_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"1024_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa1100370","volume":"366","author":"AG Zauber","year":"2012","unstructured":"Zauber AG, Winawer SJ, O\u2019Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366(8):687\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1100370.","journal-title":"N Engl J Med"},{"issue":"6","key":"1024_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jama.2014.8266","volume":"312","author":"O Holme","year":"2014","unstructured":"Holme O, Loberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 2014;312(6):606\u201315. https:\/\/doi.org\/10.1001\/jama.2014.8266.","journal-title":"JAMA"},{"issue":"6","key":"1024_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/s2468-1253(20)30009-1","volume":"5","author":"M Song","year":"2020","unstructured":"Song M, Emilsson L, Bozorg SR, et al. Risk of colorectal cancer incidence and mortality after polypectomy: a Swedish record-linkage study. Lancet Gastroenterol Hepatol. 2020;5(6):537\u201347. https:\/\/doi.org\/10.1016\/s2468-1253(20)30009-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9754","key":"1024_CR5","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","volume":"376","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(10)61543-7.","journal-title":"Lancet"},{"issue":"2","key":"1024_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/apt.13857","volume":"45","author":"L Emilsson","year":"2017","unstructured":"Emilsson L, Holme O, Bretthauer M, et al. Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention. Aliment Pharmacol Ther. 2017;45(2):193\u2013204. https:\/\/doi.org\/10.1111\/apt.13857.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"1024_CR7","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/M16-0577","volume":"164","author":"K Bibbins-Domingo","year":"2016","unstructured":"Bibbins-Domingo K, Force USPST. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2016;164(12):836\u201345. https:\/\/doi.org\/10.7326\/M16-0577.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1024_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/jnci\/djaa114","volume":"113","author":"JJ McNeil","year":"2021","unstructured":"McNeil JJ, Gibbs P, Orchard SG, et al. Effect of aspirin on cancer incidence and mortality in older adults. J Natl Cancer Inst. 2021;113(3):258\u201365. https:\/\/doi.org\/10.1093\/jnci\/djaa114.","journal-title":"J Natl Cancer Inst"},{"key":"1024_CR9","unstructured":"Guirguis-Blake JMEC, Perdue LA, Bean SI, Senger CA. Aspirin Use to Prevent Cardiovascular disease and colorectal cancer: an evidence update for the U.S. Preventive Services Task Force. Evidence synthesis. Rockville, MD: Agency for Healthcare Research and Quality; AHRQ publication no. 21-05283-EF-1. 2021;No. 211."},{"issue":"3","key":"1024_CR10","doi-asserted-by":"publisher","first-page":"458","DOI":"10.14309\/ajg.0000000000001122","volume":"116","author":"A Shaukat","year":"2021","unstructured":"Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG clinical guidelines: colorectal cancer screening 2021. Off J Am College Gastroenterol| ACG. 2021;116(3):458\u201379. https:\/\/doi.org\/10.14309\/ajg.0000000000001122.","journal-title":"Off J Am College Gastroenterol| ACG"},{"issue":"11","key":"1024_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","volume":"24","author":"JF Ludvigsson","year":"2009","unstructured":"Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659\u201367. https:\/\/doi.org\/10.1007\/s10654-009-9350-y.","journal-title":"Eur J Epidemiol"},{"key":"1024_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/CLEP.S191914","volume":"11","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson JF, Lashkariani M. Cohort profile: ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden). Clin Epidemiol. 2019;11:101\u201314. https:\/\/doi.org\/10.2147\/CLEP.S191914.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"1024_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12876-019-1134-6","volume":"20","author":"SR Bozorg","year":"2019","unstructured":"Bozorg SR, Song M, Emilsson L, Ludvigsson JF. Validation of serrated polyps (SPs) in Swedish pathology registers. BMC Gastroenterol. 2019;20(1):3. https:\/\/doi.org\/10.1186\/s12876-019-1134-6.","journal-title":"BMC Gastroenterol"},{"key":"1024_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/CLEP.S282475","volume":"13","author":"JF Ludvigsson","year":"2021","unstructured":"Ludvigsson JF, Appelros P, Askling J, et al. Adaptation of the charlson comorbidity index for register-based research in Sweden. Clin Epidemiol. 2021;13:21\u201341. https:\/\/doi.org\/10.2147\/CLEP.S282475.","journal-title":"Clin Epidemiol"},{"issue":"7","key":"1024_CR15","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM, et al. The new Swedish prescribed drug register\u2013opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726\u201335. https:\/\/doi.org\/10.1002\/pds.1294.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"1024_CR16","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1038\/bjc.2013.411","volume":"109","author":"F Jonsson","year":"2013","unstructured":"Jonsson F, Yin L, Lundholm C, Smedby KE, Czene K, Pawitan Y. Low-dose aspirin use and cancer characteristics: a population-based cohort study. Br J Cancer. 2013;109(7):1921\u20135. https:\/\/doi.org\/10.1038\/bjc.2013.411.","journal-title":"Br J Cancer"},{"issue":"1","key":"1024_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jamaoncol.2017.2752","volume":"4","author":"L Emilsson","year":"2018","unstructured":"Emilsson L, Garcia-Albeniz X, Logan RW, Caniglia EC, Kalager M, Hernan MA. Examining bias in studies of statin treatment and survival in patients with cancer. JAMA Oncol. 2018;4(1):63\u201370. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2752.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1024_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2307\/2529360","volume":"33","author":"WA Thompson Jr","year":"1977","unstructured":"Thompson WA Jr. On the treatment of grouped observations in life studies. Biometrics. 1977;33(3):463\u201370.","journal-title":"Biometrics"},{"issue":"4","key":"1024_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/00031305.2015.1089789","volume":"69","author":"TC Hesterberg","year":"2015","unstructured":"Hesterberg TC. What teachers should know about the bootstrap: resampling in the undergraduate statistics curriculum. Am Stat. 2015;69(4):371\u201386. https:\/\/doi.org\/10.1080\/00031305.2015.1089789.","journal-title":"Am Stat"},{"key":"1024_CR20","doi-asserted-by":"publisher","DOI":"10.1201\/9781315374932","volume-title":"Causal inference: What if","author":"MA Hernan","year":"2023","unstructured":"Hernan MA, Robins JM. Causal inference: What if. 1st ed. Boca Raton: CRC Press; 2023. https:\/\/doi.org\/10.1201\/9781315374932.","edition":"1"},{"key":"1024_CR21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803955","author":"JJ McNeil","year":"2018","unstructured":"McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018. https:\/\/doi.org\/10.1056\/NEJMoa1803955.","journal-title":"N Engl J Med"},{"issue":"12","key":"1024_CR22","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.amjcard.2011.02.325","volume":"107","author":"AA Bartolucci","year":"2011","unstructured":"Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107(12):1796\u2013801. https:\/\/doi.org\/10.1016\/j.amjcard.2011.02.325.","journal-title":"Am J Cardiol"},{"issue":"3","key":"1024_CR23","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1053\/j.gastro.2018.11.063","volume":"156","author":"AT Chan","year":"2019","unstructured":"Chan AT, McNeil J. Aspirin and cancer prevention in the elderly: where do we go from here? Gastroenterology. 2019;156(3):534\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2018.11.063.","journal-title":"Gastroenterology"},{"issue":"23","key":"1024_CR24","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1001\/jama.2014.15690","volume":"312","author":"Y Ikeda","year":"2014","unstructured":"Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312(23):2510\u201320. https:\/\/doi.org\/10.1001\/jama.2014.15690.","journal-title":"JAMA"},{"issue":"9759","key":"1024_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","volume":"377","author":"PM Rothwell","year":"2011","unstructured":"Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31\u201341. https:\/\/doi.org\/10.1016\/S0140-6736(10)62110-1.","journal-title":"Lancet"},{"issue":"34","key":"1024_CR26","first-page":"2584","volume":"100","author":"J Bjork","year":"2003","unstructured":"Bjork J, Borjesson L, Hertervig E, Lindmark G, Ost A. Sporadic colorectal polyps. Updated guidelines for endoscopic surveillance. Lakartidningen. 2003;100(34):2584\u20138.","journal-title":"Lakartidningen"},{"key":"1024_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450. https:\/\/doi.org\/10.1186\/1471-2458-11-450.","journal-title":"BMC Public Health"},{"issue":"3","key":"1024_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.0954-6820.1976.tb08223.x","volume":"200","author":"U de Faire","year":"1976","unstructured":"de Faire U, Friberg L, Lorich U, Lundman T. A validation of cause-of-death certification in 1156 deaths. Acta Med Scand. 1976;200(3):223\u20138.","journal-title":"Acta Med Scand"},{"issue":"5","key":"1024_CR29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3109\/02841868409136026","volume":"23","author":"B Mattsson","year":"1984","unstructured":"Mattsson B, Wallgren A. Completeness of the Swedish cancer register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol. 1984;23(5):305\u201313.","journal-title":"Acta Radiol Oncol"},{"key":"1024_CR30","volume-title":"Causal inference","author":"MA Hernan","year":"2023","unstructured":"Hernan MA, Robins JM. Causal inference. Milton Park: Taylor & Francis; 2023."},{"issue":"7","key":"1024_CR31","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gutjnl-2018-317293","volume":"68","author":"C Senore","year":"2019","unstructured":"Senore C, Basu P, Anttila A, et al. Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report. Gut. 2019;68(7):1232\u201344. https:\/\/doi.org\/10.1136\/gutjnl-2018-317293.","journal-title":"Gut"},{"issue":"7","key":"1024_CR32","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jamaoncol.2018.0736","volume":"4","author":"L Emilsson","year":"2018","unstructured":"Emilsson L, Garcia-Albeniz X, Hernan MA. Association of statin use with overall and cancer survival-reply. JAMA Oncol. 2018;4(7):1016\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0736.","journal-title":"JAMA Oncol"}],"container-title":["European Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-023-01024-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10654-023-01024-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-023-01024-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T02:03:18Z","timestamp":1697162598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10654-023-01024-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1007\/s10654-023-01024-1","relation":{},"ISSN":["0393-2990","1573-7284"],"issn-type":[{"value":"0393-2990","type":"print"},{"value":"1573-7284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"9 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Ludvigsson has coordinated a study unrelated to the present study on behalf of the Swedish IBD Quality Register (SWIBREG). That study received funding from Janssen. Authors not named here have disclosed no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"(Stockholm ethical review board): 2014\/1287\u201331\/4 and 2018\/972\u201332.<b>Transparency<\/b> The lead author (LE) affirms that this manuscript is an honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}